J 2024

Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

LAHMER, Tobias, Jon SALMANTON-GARCIA, Francesco MARCHESI, Shaimaa EL-ASHWAH, Marcio NUCCI et. al.

Basic information

Original name

Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Authors

LAHMER, Tobias, Jon SALMANTON-GARCIA, Francesco MARCHESI, Shaimaa EL-ASHWAH, Marcio NUCCI, Caroline BESSON, Federico ITRI, Ozren JAKSIC, Natasha COLOVIC, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Guldane Cengiz SEVAL, Tatjana ADZIC-VUKICEVIC, Tomas SZOTKOWSKI, Uluhan SILI, Michelina DARGENIO, van Praet JENS, van Doesum JAAP, Martin SCHOENLEIN, Zdenek RACIL, Pavel ZAK, Christian Bjorn POULSEN, Gabriele MAGLIANO, Moraima JIMENEZ, Valentina BONUOMO, Klara PIUKOVICS, Giulia DRAGONETTI, Fatih DEMIRKAN, Ola BLENNOW, Toni VALKOVIC, Da Silva Maria GOMES, Johan MAERTENS, Andreas GLENTHOJ, Noemi FERNANDEZ, Rui BERGANTIM, Luisa VERGA, Verena PETZER, Ali S OMRANI, Gustavo-Adolfo MENDEZ, Marina MACHADO, Marie-Pierre LEDOUX, Rebeca BAILEN, Rafael F DUARTE, Del Principe Maria ILARIA, Francesca FARINA, Sonia MARTIN-PEREZ, Julio DAVILA-VALLS, Monia MARCHETTI, Yavuz M BILGIN, Nicola S FRACCHIOLLA, Chiara CATTANEO, Ildefonso ESPIGADO, Raul CORDOBA, Graham P COLLINS, Jorge LABRADOR, Iker FALCES-ROMERO, Lucia PREZIOSO, Stef MEERS, Francesco PASSAMONTI, Caterina BUQUICCHIO, Alberto LOPEZ-GARCIA, Austin KULASEKARARAJ, Irati ORMAZABAL-VELEZ, Annarosa CUCCARO, Carolina GARCIA-VIDAL, Alessandro BUSCA, Milan NAVRATIL, de Jonge NICK, Monika M BIERNAT, Anna GUIDETTI, Ghaith ABU-ZEINAH, Michail SAMARKOS, Amalia ANASTASOPOULOU, de Ramon CRISTINA, Tomas Jose GONZALEZ-LOPEZ, Martin HOENIGL, Olimpia FINIZIO, Laszlo Imre PINCZES, Natasha ALI, Antonio VENA, Carlo TASCINI, Zlate STOJANOSKI, Maria MERELLI, Ziad EMARAH, Milena KOHN, Aleksandra BARAC, Milos MLADENOVIC, Bojana MISKOVIC, Osman ILHAN, Gokce Melis COLAK, Martin CERNAN, Stefanie K GRAEFE, Emanuele AMMATUNA, Michaela HANAKOVA, Benjamin VISEK, Alba CABIRTA, Anna NORDLANDER, Raquel Nunes RODRIGUES, Ditte Stampe HERSBY, Giovanni Paolo Maria ZAMBROTTA, Dominik WOLF, Lucia NUNEZ-MARTIN-BUITRAGO, Elena ARELLANO, Francesco Aiello TOMMASO, Ramon GARCIA-SANZ, Juergen PRATTES, Matthias EGGER, Alessandro LIMONGELLI, Martina BAVASTRO, Milche CVETANOSKI, Miriam DIBOS, Sebastian RASCH, Laman RAHIMLI, Oliver A CORNELY and Livio PAGANO

Edition

Infection, HEIDELBERG, Springer, 2024, 0300-8126

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.500 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s15010-023-02169-7

UT WoS

001183232800001

Keywords in English

COVID-19; haematological malignancies

Tags

14110212, rivok

Tags

International impact, Reviewed
Změněno: 12/7/2024 13:45, Mgr. Tereza Miškechová

Abstract

V originále

The risk for a severe coronavirus disease 2019 (COVID-19) with need for an intensive care unit (ICU) admission in a non-immunocompromised vaccinated population dropped from 5% at the beginning of the pandemic to at least 0.2% and is still decreasing since the omicron strain dominates the COVID-19 pandemic [1]. Beyond the risk factors identified for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection like male sex, older age, and comorbidities such as cardiovascular disease, lung disease or obesity, patients with a history of malignancy, specifically patients with haematological malignancy, are prone to develop a complicated SARS-CoV-2 infection with need for ICU which is still associated with poorer clinical outcome. The circumstances of a widely heterogenous population with regards to the type of haematological malignancy, extent of disease, haematological malignancy treatment history, and baseline performance status are even more challenging in the environment of an ICU. Although, data referring to critically ill COVID-19 patients regarding treatment strategies and outcome are widely available, data referring to critically ill patients with haematological malignancy are scarce and underreported. The aim of this study is to analyze the epidemiology, risk factors and outcome of patients with haematological malignancy with need for an ICU setting using the data from the large-scale EPICOVIDEHA registry of the European Hematology Association—Scientific Working Group Infectious in Hematology (EHA-SWG).
Displayed: 1/11/2024 08:28